Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.
Journal: ESMO open
Published: January 25, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: September 22, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Journal: Molecular cancer therapeutics
Published: February 01, 2023
Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
Journal: British journal of clinical pharmacology
Published: November 14, 2022
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 24, 2022
Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.
Journal: Frontiers in immunology
Published: October 14, 2020
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 02, 2019
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia.
Journal: PloS one
Published: March 27, 2019
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.
Journal: Cancer discovery
Published: November 13, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026